Business Context and Reporting Period
This Form 8-K was filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on April 25, 2017. The report details a strategic partnership entered into on the same date with Acoustic Medsystems, Inc. (AMS) to develop and commercialize medical technologies for pancreatic procedures.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial implication is the issuance of equity as consideration for the agreement.
- Equity Issuance: The Company agreed to issue up to 115,000 shares of unregistered common stock to AMS.
- Payment Structure: Shares are issuable upon execution of the agreement and upon the achievement of certain milestones.
Material Changes
The material change reported is the entry into a Material Definitive Agreement (License and Collaboration Agreement) with AMS. Key terms include:
- Collaboration Scope: Integration of AMS's TheraVision system into the field of pancreatic medical procedures via vessels, ducts, or percutaneous access.
- Intellectual Property: MRI Interventions will exclusively own new IP developed through the collaboration.
- Commercial Rights: AMS granted MRI Interventions an exclusive right to sell, market, license, and distribute the AMS System within the defined field.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the collaboration but provides no specific financial guidance or revenue projections. Management notes that actual results may differ materially due to market conditions and other uncertainties. The Company refers investors to the "Risk Factors" section of its Annual Report on Form 10-K filed on March 9, 2017, for a comprehensive description of risks.
Investor Verification Checklist
- Verify the exact number of shares issued immediately versus those contingent on future milestones.
- Review the full text of the License and Collaboration Agreement (to be filed in the 10-Q for the quarter ended March 31, 2017) for detailed milestone definitions.
- Confirm the dilution impact of the 115,000 shares on existing shareholders.
- Assess the regulatory status of the TheraVision system for the specific pancreatic applications mentioned.